Form 4: Raymond Debbane Reports Changes in Beneficial Ownership of Lexicon Pharmaceuticals
SEC Form 4 Filing
Raymond Debbane, a director of Lexicon Pharmaceuticals, reports a transaction involving restricted stock units converting to common stock.
Summary
- On May 13, 2025, Raymond Debbane reported a transaction involving Lexicon Pharmaceuticals common stock.
- Debbane acquired 36,810 shares of common stock upon the vesting of restricted stock units.
- The price per share for the transaction was $0.
- Following the transaction, Debbane directly owns 1,385,689 shares of common stock.
- Debbane indirectly owns 44,370,107 shares through Invus L.P., Invus Public Equities L.P., Invus US Partners LLC and related parties.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard part of regulatory compliance for publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine vesting of previously granted compensation.
Key Dates
| Date | Description |
|---|---|
| 05/13/2025 | Date of transaction: vesting of restricted stock units and acquisition of common stock |
Keywords
Beneficial Ownership, Lexicon Pharmaceuticals, Raymond Debbane, Form 4, LXRX, Restricted Stock Units, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.